| | | PUBLICATIONS (Ranked by impact factor of the journal) |
The Noncoding RNAs SNORD50A and SNORD50B Bind K-Ras and Are Recurrently Deleted in Human Cancer
To explore their role in cancer, investigators compared 5,473 tumor-normal genome pairs to identify small nucleolar RNAs (snoRNAs) with frequent copy number loss. The SNORD50A-SNORD50B snoRNA locus was deleted in 10–40% of 12 common cancers, where its loss was associated with reduced survival. [Nat Genet] Abstract
|
Press Release
Trastuzumab Emtansine (T-DM1) Renders HER2+ Breast Cancer Highly Susceptible to CTLA-4/PD-1 Blockade
Scientists showed that drug resistance can be overcome with trastuzumab emtansine, an antibody-drug conjugate that combines the human epidermal growth factor receptor 2 (HER2)-targeting ability of trastuzumab with a cytotoxic drug, which the antibody delivers directly to the tumor. [Sci Transl Med] Abstract
|
Press Release
Type 1 Diabetes Immunotherapy Using Polyclonal Regulatory T Cells
Researchers report a Phase I trial of adoptive regulatory T cells (Tregs) immunotherapy to repair or replace Tregs in type 1 diabetics. The ex vivo–expanded polyclonal Tregs were long-lived after transfer and retained a broad Tregs phenotype long-term. [Sci Transl Med] Abstract
|
Press Release
PDL1 Regulation by p53 via miR-34
Investigators showed that PDL1 is regulated by p53 via miR-34. Therapeutic delivery of miR-34a–loaded liposomes promoted tumor-infiltrating lymphocytes and reduced CD8+PD1+ cells in vivo. [J Natl Cancer Inst] Abstract
|
Press Release
Engraftment of Human Induced Pluripotent Stem Cell-Derived Hepatocytes in Immunocompetent Mice via 3D Co-Aggregation and Encapsulation
Scientists demonstrated successful engraftment of human induced pluripotent stem cell-derived hepatocyte-like cells in immunocompetent mice by pre-engineering 3D cell co-aggregates with stromal cells followed by encapsulation in recently developed biocompatible hydrogel capsules. [Sci Rep] Full Article
Bone Marrow Mesenchymal Stem Cell Aggregate: An Optimal Cell Therapy for Full-Layer Cutaneous Wound Vascularization and Regeneration
Cell-aggregates constructed with green fluorescent protein-expressing rat bone marrow mesenchymal stem cells were applied to rat acute full-layer cutaneous wound model to confirm its pro-regeneration ability and compare its regenerative efficacy with the currently thriving subcutaneous and intravenous stem cell administration strategy, with a view to sensing the advantages, disadvantages and the mechanism behind. [Sci Rep] Full Article
In Situ Vascular Regeneration Using Substance P-Immobilized Poly(L-Lactide-Co-ε-Caprolactone) Scaffolds: Stem Cell Recruitment, Angiogenesis, and Tissue Regeneration
Investigators fabricated scaffolds by mixing appropriate proportions of linear poly (l-lactide-co-ε-caprolactone) (PLCL) and substance P-immobilized PLCL. The biocompatibility and biological performance of the scaffolds were evaluated by in vivo experiments involving subcutaneous scaffold implantations in Sprague-Dawley rats for up to 28 days followed by histological and immunohistochemical studies. [Eur Cell Mater] Abstract
|
Full Article
Arterial Decellularized Scaffolds Produced Using an Innovative Automatic System
Researchers developed an innovative system for the automatic decellularization of blood vessels, used to process pig arteries. Decellularized scaffolds were seeded on the inner layer with human endothelial cells and implanted as iliac artery replacement in four pharmacologically immune-compromised pigs. [Cells Tissues Organs] Abstract
|
| |
| REVIEWS |
Humanized Mouse Models for Transplant Immunology
The authors highlight recent advances in the development of humanized mice and their use as preclinical models for the study of human allograft responses. [Am J Transplant] Abstract
Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research fields.
|
| | | BUSINESS |
New EU Project Designed to Link Diagnosis and Treatment of Diseases over the Long Term
An international team from four EU countries plans to use an innovative concept to improve the use of companion diagnostics in disease and develop new approaches to therapy in the long term. [Johannes Gutenberg-Universität Mainz] Press Release
New Agreement to Open the Door to Next Generation Cell Therapies
A new collaboration agreement has been announced by Macquarie University and clinical-stage regenerative medicine company Regeneus Ltd., to commercialize a breakthrough cell selection technology that for the first time allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies. [Regeneus Ltd.] Press Release
CPRIT Awards Faculty $19.6 Million for Research in Cervical, Breast, Lung, Colon, and Pediatric Cancers, and Cancer Biology
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $19.6 million in research grants to improve preventive, diagnostic, and therapeutic services relating to cervical, breast, lung, colon, and pediatric cancers, as well as to improve scientific understanding of cancer biology. [UT Southwestern Medical Center] Press Release
MassGeneral Hospital for Children Receives Grant to Pursue Novel Antibacterial Strategy
MassGeneral Hospital for Children has been named a Grand Challenges Explorations winner through an initiative funded by the Bill & Melinda Gates Foundation. Researchers will pursue an innovative global health and development research project, titled “Disarming Type III Secretion System of Enteric Pathogens.” [MassGeneral Hospital (EurekAlert!)] Press Release
Pembrolizumab in Advanced Melanoma: Added Benefit for Certain Patients
The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether pembrolizumab offers an added benefit over the appropriate comparator therapy. According to the findings, an added benefit can be derived for different patient groups. [German Institute for Quality and Efficiency in Health Care] Press Release
New Patent Paves Way for Breast Cancer Prevention
George Mason University researchers have patented a new breast cancer treatment that uses a common malaria drug to stop cancer in its beginning stages. Chloroquine, a drug commonly given to prevent or treat malaria, targets ductal carcinoma in situ, the most common type of pre-invasive breast cancer. [George Mason University] Press Release
FDA Approves Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer
The U.S. Food and Drug Administration approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced squamous non-small cell lung cancer who have not previously received medication specifically for treating their advanced lung cancer. [U.S. Food and Drug Administration] Press Release
Adaptimmune Initiates Phase I/II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting
Adaptimmune Therapeutics plc announced that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV non-small cell lung cancer. [Adaptimmune Therapeutics plc] Press Release
|
|
